FDA Approves Expanded Use of Vraylar (cariprazine) in the Treatment of Bipolar Depression
DUBLIN and BUDAPEST, Hungary, May 28, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN) and Gedeon Richter Plc. today announced that the U.S. Food and Drug Administration (FDA) has approved a supplemental New Drug Application (sNDA) for Vraylar...
Source: Drugs.com - New Drug Approvals - Category: Drugs & Pharmacology Source Type: news
More News: Allergy | Bipolar | Depression | Drugs & Pharmacology | Food and Drug Administration (FDA) | Hungary Health | Mania | New Drug Applications